AIR-BX1 and AIR-BX2 were two double-blind , multicentre , randomised , placebo-controlled phase 3 trials , which included patients aged 18 years or older who had bronchiectasis and history of positive sputum or bronchoscopic culture for target Gram-negative organisms .